Breaking News Instant updates and real-time market news.

CVS

CVS Health

$87.43

-1.37 (-1.54%)

, ABT

Abbott

$40.80

0.01 (0.02%)

11:02
10/17/16
10/17
11:02
10/17/16
11:02

CVS Health's Omnicare to pay $28M to settle kickback allegations

Omnicare has agreed to pay $28.125M to resolve allegations that it solicited and received kickbacks from pharmaceutical manufacturer Abbott Laboratories (ABT) in exchange for promoting the prescription drug, Depakote, for nursing home patients. CVS Health Corporation (CVS), which is headquartered in Rhode Island, acquired Ohio-based Omnicare in 2015, approximately six years after Omnicare ended the conduct that gave rise to the settlement. According to the government's complaint, Omnicare disguised the kickbacks it received from Abbott in a variety of ways. Abbott allegedly made payments to Omnicare described as "grants" and "educational funding," even though their true purpose was to induce Omnicare to recommend Depakote. Approximately $20.3M of the settlement will go to the United States, while $7.8M has been allocated to cover Medicaid program claims by states that elect to participate in the settlement. The Medicaid program is jointly funded by the federal and state governments. This matter was jointly handled by the Civil Division's Commercial Litigation Branch, the U.S. Attorney's Office for the Western District of Virginia, HHS-OIG, the Office of the Attorney General for the Commonwealth of Virginia and the National Association of Medicaid Fraud Control Units.

CVS

CVS Health

$87.43

-1.37 (-1.54%)

ABT

Abbott

$40.80

0.01 (0.02%)

  • 19

    Oct

  • 06

    Nov

CVS CVS Health
$87.43

-1.37 (-1.54%)

09/30/16
LEER
09/30/16
NO CHANGE
Target $105
LEER
Outperform
CVS Health price target lowered to $105 on pricing concerns at Leerink
Leerink analyst David Larsen said that after speaking with a PBM and Managed Care specialist and performing an analysis of IMS data he now believes that drug pricing has slowed materially over the past 9 months. Given that conclusion, Larsen is lowering his revenue and EPS estimates for CVS Health for the second half of this year and for 2017 and lowered his price target on CVS shares to $105 from $110. However, he keeps an Outperform rating on the stock, since he is still positive on CVS for the long-term.
10/05/16
UBSW
10/05/16
INITIATION
Target $107
UBSW
Buy
CVS Health initiated with a Buy at UBS
Target $107.
10/06/16
10/06/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boeing (BA) initiated with an Outperform at Baird. 2. AMC Networks (AMCX) initiated with an Outperform at FBN Securities. 3. CVS Health (CVS) initiated with a Buy at UBS. 4. L-3 Communications (LLL) initiated with an Outperform at Baird. 5. Raytheon (RTN) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
LEER
10/13/16
NO CHANGE
Target $105
LEER
Outperform
Tricare announcement not material to CVS Health, says Leerink
Leerink analyst David Larsen notes that Tricare recently announced that CVS Health (CVS) will be excluded from its network effective December 1 and Walgreens Boots Alliance (WBA) will be in-network. While there are over 127M scripts associated with Tricare each year, the analyst estimates that just about 30.6M of these prescriptions are "retail" and as a result Larsen does not believe that CVS' exclusion from the Tricare network will be material. He remains positive on CVS, and reiterates an Outperform rating and $105 price target on the company's shares.
ABT Abbott
$40.80

0.01 (0.02%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

SBGSY

Schneider Electric

$13.70

-0.115 (-0.83%)

15:24
02/24/17
02/24
15:24
02/24/17
15:24
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

SBGSY

Schneider Electric

$13.70

-0.115 (-0.83%)

15:23
02/24/17
02/24
15:23
02/24/17
15:23
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

AVP

Avon Products

$4.43

0.18 (4.24%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Hot Stocks
Avon Products rises after COO discloses purchase of 150K shares »

Avon Products COO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

15:21
02/24/17
02/24
15:21
02/24/17
15:21
Options
Apple expiring ATM straddle is active as shares pin to $136 into the final hour »

Apple expiring ATM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

PPRUY

Kering

$24.38

0.055 (0.23%)

15:19
02/24/17
02/24
15:19
02/24/17
15:19
Conference/Events
Kering management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

$NSD

NASDAQ Market Internals

15:17
02/24/17
02/24
15:17
02/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/24/17
02/24
15:16
02/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$128.69

-1.04 (-0.80%)

15:14
02/24/17
02/24
15:14
02/24/17
15:14
Conference/Events
Aetna management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WMT

Wal-Mart

$72.37

1.055 (1.48%)

, BBY

Best Buy

$45.75

1.435 (3.24%)

15:12
02/24/17
02/24
15:12
02/24/17
15:12
Periodicals
White House denying Cohn comments on border-adjustment tax, Axios says »

The White House has…

WMT

Wal-Mart

$72.37

1.055 (1.48%)

BBY

Best Buy

$45.75

1.435 (3.24%)

COST

Costco

$175.85

-0.66 (-0.37%)

TGT

Target

$66.59

1.61 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PYPL

PayPal

$42.53

0.11 (0.26%)

15:11
02/24/17
02/24
15:11
02/24/17
15:11
Options
$1M premium seller in Paypal »

$1M premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

15:09
02/24/17
02/24
15:09
02/24/17
15:09
Conference/Events
West Corp. to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FCNCA

First Citizens

$363.85

0.03 (0.01%)

15:07
02/24/17
02/24
15:07
02/24/17
15:07
Hot Stocks
Breaking Hot Stocks news story on First Citizens »

Vanguard reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTR

Dollar Tree

$77.57

-0.97 (-1.24%)

15:06
02/24/17
02/24
15:06
02/24/17
15:06
Options
Dollar Tree call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Meet Aduro: CEO Isaacs says partnerships help development efforts »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$1.42

-0.05 (-3.40%)

15:01
02/24/17
02/24
15:01
02/24/17
15:01
Hot Stocks
Breaking Hot Stocks news story on Sierra Oncology »

Frazier Healthcare VI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGI

Endurance

$9.00

-0.3 (-3.23%)

14:59
02/24/17
02/24
14:59
02/24/17
14:59
Rumors
Rumor moving shares of Endurance »

Rumor: Endurance late day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WSTC

West Corp.

$24.66

-0.09 (-0.36%)

14:57
02/24/17
02/24
14:57
02/24/17
14:57
Periodicals
West Corp. buyout looks challenging, Dealreporter says »

Private equity firms have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LUK

Leucadia

$25.63

-0.09 (-0.35%)

14:50
02/24/17
02/24
14:50
02/24/17
14:50
Options
Leucadia options imply 2.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWJ

iShares MSCI Japan Index Fund

$51.43

-0.205 (-0.40%)

14:41
02/24/17
02/24
14:41
02/24/17
14:41
Options
iShares Japan Fund draws a notable option block »

iShares Japan Fund draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RP

RealPage

$33.70

-0.5 (-1.46%)

14:36
02/24/17
02/24
14:36
02/24/17
14:36
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 02

    Mar

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:29
02/24/17
02/24
14:29
02/24/17
14:29
Hot Stocks
Volkswagen took EUR6.4B in charges from diesel scandal in FY16 »

Volkswagen said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

, NVS

Novartis

$77.15

-0.2959 (-0.38%)

14:27
02/24/17
02/24
14:27
02/24/17
14:27
Hot Stocks
Meet Aduro: Progress across 3 main platforms seen in 2017 »

In an exclusive interview…

ADRO

Aduro Biotech

$11.15

-0.25 (-2.19%)

NVS

Novartis

$77.15

-0.2959 (-0.38%)

JNJ

Johnson & Johnson

$122.09

1.19 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

  • 26

    Jun

SU

Suncor

$31.55

-1.12 (-3.43%)

14:26
02/24/17
02/24
14:26
02/24/17
14:26
Options
Suncor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$30.91

0.135 (0.44%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Hot Stocks
Volkswagen sees FY17 operating return on sales 6%-7% »

The Volkswagen Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$25.55

0.35 (1.39%)

14:21
02/24/17
02/24
14:21
02/24/17
14:21
Periodicals
Spark Energy hires Morgan Stanley to advise on potential sale, SparkSpread says »

Spark Energy has retained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.